These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 24043936)

  • 1. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
    Karabis A; Lindner L; Mocarski M; Huisman E; Greening A
    Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
    Cope S; Donohue JF; Jansen JP; Kraemer M; Capkun-Niggli G; Baldwin M; Buckley F; Ellis A; Jones P
    Respir Res; 2013 Oct; 14(1):100. PubMed ID: 24093477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
    Medic G; Lindner L; van der Weijden M; Karabis A
    Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
    Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
    COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclidinium bromide for stable chronic obstructive pulmonary disease.
    Ni H; Soe Z; Moe S
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
    Manoharan A; Morrison AE; Lipworth BJ
    Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
    Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
    Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
    Chapman KR; Beeh KM; Beier J; Bateman ED; D'Urzo A; Nutbrown R; Henley M; Chen H; Overend T; D'Andrea P
    BMC Pulm Med; 2014 Jan; 14():4. PubMed ID: 24438744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
    Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
    Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
    BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
    Cope S; Zhang J; Williams J; Jansen JP
    BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.
    Schlueter M; Gonzalez-Rojas N; Baldwin M; Groenke L; Voss F; Reason T
    Ther Adv Respir Dis; 2016 Apr; 10(2):89-104. PubMed ID: 26746383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
    Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.